Communiqués Infinity Pharmaceuticals, Inc.

Actions

INFI.Q

US45665G3039

Services et équipements environnementaux

Cours en clôture OTC Markets Autres places de cotation 28/07/2026			Varia. 5j.	Varia. 1 janv.
0,000001 ^USD	0,00 %		0,00 %	-

25/03/24	Infinity Pharmaceuticals, Inc. a cessé ses activités	CI
15/02/24	Une société d'investissement inconnue dans le secteur de la santé a acquis la quasi-totalité des actifs d'Infinity Pharmaceuticals, Inc. (OTCPK:INFI.Q).	CI

Communiqués

30/09/23	Infinity Pharmaceuticals : Bankruptcy - Form 8-K	PU
19/08/23	INFINITY ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Infinity Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm	BU
25/07/23	Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan	BU
24/07/23	Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma	BU
17/07/23	Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma	AQ
14/07/23	Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma	BU
11/07/23	Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab in Patients with Squamous Cell Cancer of the Head and Neck	AQ
10/07/23	Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®) in Patients with Squamous Cell Cancer of the Head and Neck (SCCHN)	BU
05/07/23	ISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.	BU
20/06/23	INFINITY PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
15/06/23	MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates	BU
15/06/23	INFINITY PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Infinity Pharmaceuticals, Inc. - INFI	BU
10/05/23	Infinity: Q1 Earnings Snapshot	AQ
14/04/23	Infinity Pharmaceuticals Announces Two Upcoming Presentations on PI3K- and Eganelisib by Dr. Judith Varner at the 2023 Annual Meeting of the American Association of Cancer Research	AQ
13/04/23	Infinity Pharmaceuticals Announces Two Upcoming Presentations on PI3K-γ and Eganelisib by Dr. Judith Varner at the 2023 Annual Meeting of the American Association of Cancer Research	BU
07/04/23	INFINITY PHARMACEUTICALS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
28/03/23	Infinity Pharmaceuticals Reports Full Year 2022 Financial Results	BU
28/03/23	INFINITY PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
27/02/23	INFINITY PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Infinity Pharmaceuticals, Inc. - INFI	BU
25/02/23	Infinity Pharmaceuticals : MEI Pharma and Infinity Pharmaceuticals Merger Announcement	PU
23/02/23	INFINITY PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
30/12/22	INFINITY PHARMACEUTICALS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
22/11/22	Infinity Pharmaceuticals to Participate in Piper Sandler 34th Annual Healthcare Conference	BU
14/11/22	Infinity: Q3 Earnings Snapshot	AQ
14/11/22	Infinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update	BU